Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

IMPORTANCE: Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory to imatinib mesylate, treatment with sunitinib malate followed by regorafenib provides tumor control; however, additional act...

詳細記述

保存先:
書誌詳細
出版年:JAMA Oncol
主要な著者: Schuetze, Scott M., Bolejack, Vanessa, Thomas, Dafydd G., von Mehren, Margaret, Patel, Shreyaskumar, Samuels, Brian, Choy, Edwin, D’Amato, Gina, Staddon, Arthur P., Ganjoo, Kristen N., Chow, Warren A., Rushing, Daniel A., Forscher, Charles A., Priebat, Dennis A., Loeb, David M., Chugh, Rashmi, Okuno, Scott, Reinke, Denise K., Baker, Laurence H.
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2018
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145709/
https://ncbi.nlm.nih.gov/pubmed/29710216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.0601
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料